


Contact :

Dr. Salih Alwan Ali
Kapelsesteenweg 217
B-2180 Ekeren-Donk (Antwerpen)
Belgium
+32 (0) 3 644 8541
+32 (0) 478 391136
medstat.belgium@telenet.be



About MedStat Belgium

Founded in 1996, MedStat Belgium prides themselves on their years of experience, superb repeat client rate, and the ability to consistently exceed the expectations by applying flexibility, commitment and responsiveness to clients' needs while maintaining highest degree of professional ethics and integrity.

Over the years, MedStat Belgium has earned a reputation for providing unrivalled quality, attentive client service and with very reasonable charges.

At MedStat Belgium, we pledge an uncompromising commitment to excellence. Contact us today to find out how we can provide you with timely services.

Services and Solutions

- **Statistical Analysis and Report Writing for :**

- Non-interventional, Observational Research
- Phase IV Clinical trials
- Epidemiologic Studies
- Large Electronic Health Record Databases and
- Patient-reported Outcomes / Health-related Quality of life (HR-QoL) Research.

Our medical statisticians are experts in applying both simple and sophisticated statistical techniques such as Multivariate data analysis, multilevel modeling, Growth Curve models and Factor analysis (Latent variables).

Also in dealing with missing data (MCAR, MAR and NMAR) which in many instances determine which methods of analysis are appropriate for longitudinal studies such as HR-QoL studies.

- **Systematic Literature Reviews and Meta-Analyses.**

- **Up-to-date Literature Reviews and Report writing for :**

- Chronic conditions (e.g. cancer)
- Infectious diseases
- Rare (Orphan) diseases, and
- For any drug or regimen in developments and/or approved.

The report covers the following topics :

- Disease overview: Background, Pathophysiology, Etiology, Epidemiology of the disease including incidence/prevalence data in the five largest markets in Europe (Italy, France, Germany, Spain and the UK) and the USA, and disease Prognosis,
- Current Treatment Options (First- and Second-line): Results from Key/Pivotal clinical trials and latest developments emerging from annual meetings summarizing main Efficacy and Safety data,
- Rate of relapse in cancer in local and distant disease and estimated number of potential candidate for systemic therapy yearly,
- Comparing the new phase 3 data with the EMEA's and FDA's approved compounds clinical trial results,
- Emerging drug therapy: Summarizing main efficacy and safety data,
- Treatment Guidelines (if any),
- Ongoing clinical trials sponsored by the industry and Potential drugs in development,
- Gaps and areas of unmet research, and
- Summary and Conclusions.